Personalis (NASDAQ:PSNL) Shares Gap Down on Analyst Downgrade

Posted by George Bondi on Jul 22nd, 2026

Personalis, Inc. (NASDAQ:PSNL – Get Free Report)’s share price gapped down before the market opened on Monday after Lake Street Capital downgraded the stock from a buy rating to a hold rating. The stock had previously closed at $15.39, but opened at $14.56. Lake Street Capital now has a $16.25 price target on the stock. Personalis shares last traded at $14.0830, with a volume of 3,002,381 shares.

Other analysts have also recently issued reports about the company. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Morgan Stanley raised their target price on Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. TD Cowen reaffirmed a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. BTIG Research reduced their price target on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Finally, Needham & Company LLC cut Personalis from a “buy” rating to a “hold” rating in a research note on Monday. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $14.25.

Read Our Latest Stock Report on PSNL

Insider Buying and Selling

In related news, CFO Aaron Tachibana sold 4,982 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $14.00, for a total transaction of $69,748.00. Following the sale, the chief financial officer owned 198,833 shares of the company’s stock, valued at $2,783,662. The trade was a 2.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total value of $1,508,000.00. Following the completion of the sale, the chief executive officer owned 235,986 shares of the company’s stock, valued at $3,558,668.88. This trade represents a 29.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 435,032 shares of company stock valued at $5,599,929. Company insiders own 4.20% of the company’s stock.

Personalis News Roundup

Here are the key news stories impacting Personalis this week:

Positive Sentiment: The Tempus deal gives Personalis shareholders a clear cash/stock exit value at $16.25 per share, creating a takeover premium versus recent trading levels. Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
Positive Sentiment: The acquisition validates Personalis’ MRD and cancer-monitoring technology, which Tempus said will strengthen its AI-enabled precision oncology platform and expand its cancer recurrence-testing capabilities. Tempus to acquire Personalis for $1.5 billion
Neutral Sentiment: Several investor-rights law firms, including Halper Sadeh, Brodsky & Smith, Ademi, and Julie & Holleman, have launched investigations into whether the sale terms are fair to shareholders, which may add headline noise but does not change the deal economics. Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?
Neutral Sentiment: Analyst commentary has been mixed, with BTIG raising its price target to $16.25 while Needham downgraded the stock to hold, reflecting debate over valuation rather than a change in the merger terms. Analyst coverage references
Negative Sentiment: Some market coverage notes that both PSNL and TEM traded lower after the deal announcement, suggesting investors may be concerned about execution risk, deal structure, or limited upside beyond the acquisition price. Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink

Institutional Trading of Personalis

Hedge funds and other institutional investors have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Personalis by 273.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after buying an additional 7,896,714 shares during the period. Aberdeen Group plc raised its position in Personalis by 36.1% in the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after acquiring an additional 861,948 shares in the last quarter. Kennedy Capital Management LLC raised its position in Personalis by 196.2% in the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after acquiring an additional 1,281,695 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Personalis by 1,332.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock valued at $11,531,000 after acquiring an additional 1,347,439 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in Personalis by 11.0% in the 3rd quarter. Millennium Management LLC now owns 1,210,754 shares of the company’s stock valued at $7,894,000 after acquiring an additional 120,027 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

Personalis Trading Up 0.7%

The company’s 50-day moving average price is $11.24 and its two-hundred day moving average price is $8.98. The company has a market cap of $1.41 billion, a P/E ratio of -13.18 and a beta of 2.24.

Personalis (NASDAQ:PSNL – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The business had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.48 million. Equities analysts forecast that Personalis, Inc. will post -1.07 earnings per share for the current year.

Personalis Company Profile

(Get Free Report)

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

Featured Stories

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.